Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

OBJECTIVE: To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective. DESIGN: A within-trial cost-utili...

Descripción completa

Detalles Bibliográficos
Autores principales: Dakin, Helen A, Wordsworth, Sarah, Rogers, Chris A, Abangma, Giselle, Raftery, James, Harding, Simon P, Lotery, Andrew J, Downes, Susan M, Chakravarthy, Usha, Reeves, Barnaby C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120317/
https://www.ncbi.nlm.nih.gov/pubmed/25079928
http://dx.doi.org/10.1136/bmjopen-2014-005094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120317/
https://www.ncbi.nlm.nih.gov/pubmed/25079928
http://dx.doi.org/10.1136/bmjopen-2014-005094

Ejemplares similares